RE:RE:RE:RE:ASCO Presentation - 28% CR at 450 DaysTwo months ago Ferring Pharmaceuticals received FDA approval for Adstiladrin for high-risk, BCG-unresponsive NMIBC based on a CR rate at 12 months of 23.5%. Today Theralase announced to a symposium of genitourinary oncologists a CR rate at 15 months of 28% for the same indication. TLD1433 pdt has higher efficacy, a more enduring response, and better results are likely on the way.
On May 1 Theralase will be presenting updated (and very likely better) results to the 20,000 member AUA, (the American Urology Association).
Up to now TLD1433 pdt has not been part of the public conversation among urologists with respect to NMIBC options. I think that's about to change. Also, IMHO, FDA approval is on it's way.